Combinatorial pharmacogenomics and improved patient outcomes in depression: Treatment by primary care physicians or psychiatrists
- 1 September 2018
- journal article
- research article
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 104, 157-162
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Research and Innovation
This publication has 21 references indexed in Scilit:
- Genotype, phenotype, and medication recommendation agreement among commercial pharmacogenetic-based decision support toolsThe Pharmacogenomics Journal, 2018
- Economic Utility: Combinatorial Pharmacogenomics and Medication Cost Savings for Mental Health Care in a Primary Care SettingClinical Therapeutics, 2017
- Population Of US Practicing Psychiatrists Declined, 2003–13, Which May Help Explain Poor Access To Mental Health CareHealth Affairs, 2016
- The Economic Burden of Adults With Major Depressive Disorder in the United States (2005 and 2010)The Journal of Clinical Psychiatry, 2015
- Clinical validity: Combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypesThe Pharmacogenomics Journal, 2015
- Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient settingPharmacogenetics and Genomics, 2013
- Using a pharmacogenomic algorithm to guide the treatment of depressionTranslational Psychiatry, 2012
- Primary Versus Specialty Care Outcomes for Depressed Outpatients Managed with Measurement-Based Care: Results from STAR*DJournal of General Internal Medicine, 2008
- Major Depression Symptoms in Primary Care and Psychiatric Care Settings: A Cross-Sectional AnalysisThe Annals of Family Medicine, 2007
- A direct comparison of presenting characteristics of depressed outpatients from primary vs. specialty care settings: preliminary findings from the STAR*D clinical trialGeneral Hospital Psychiatry, 2005